The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become increasingly evident with the discovery of genetic variants that affect expression and/or function of a given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies have associated alterations in substrate uptake with the presence of SNPs. Here, we summarize the current knowledge on the functional and phenotypic consequences of genetic variation in intestinally, hepatically and renally expressed members of the organic anion-transporting polypeptide family (OATPs; SLC21/SLCO family), the organic anion and organic cation transporters (OATs/OCTs; SLC22 family) and the peptide transporter-1 (PEPT1; SLC15 family).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/14622416.9.5.597 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Harnessing Pharmacogenomics for Personalized Medicine: Tailoring Drug Therapy to Genetic Profiles.
Zhongguo Ying Yong Sheng Li Xue Za Zhi
December 2024
Maharaja Agrasen Himalayan Garhwal University, Pauri Garhwal, Uttarakhand, India, 246169.
This study means to investigate the capability of pharmacogenetics which can customize drug treatment through altered treatment of male genetic profiles. We finished hereditary profiling utilizing cutting edge sequencing (NGS) to figure out the key hereditary varieties that impact the medications metabolic adequacy and security. Patients were checked for a very long time to evaluate clinical results including ADRs and general wellness.
View Article and Find Full Text PDFImpact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study.
Pharmacogenomics
December 2024
Department of Anesthesiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Aim: The study aimed to examine the association of two selected candidate SNPs rs2242480 (CYP3A4) and rs1045642 (ABCB1) with metabolic ratio of plasma norfentanyl to fentanyl concentrations in patients undergoing major breast surgeries.
Methods: The retrospective cross-sectional study was done in 257 female patients. DNA extraction, genotyping of selected SNPs, and drug levels measurement were employed.
Lung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations.
Per Med
December 2024
Faculty of Biology, Kabul University, Afghanistan.
Article Synopsis
- - Lung cancer is the most lethal type of cancer worldwide, and the main treatment, cisplatin, often leads to rapid resistance and severe side effects like hearing loss and kidney damage.
- - This review focuses on the link between specific gene variations (single nucleotide polymorphisms or SNPs) and the toxicity caused by cisplatin.
- - The authors suggest using knowledge about these genetic variations to reduce the chances of treatment failure and minimize harmful side effects from cisplatin.
SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report.
Br J Clin Pharmacol
January 2025
Department of Medicine, Western Ontario, London, ON, Canada.
We report a case of an adult woman of African ancestry who was hospitalized with statin induced- rhabdomyolysis. The patient presented to the emergency room with a 2-week history of worsening muscle pain, nausea, vomiting and low oral intake, 1 month after starting 40 mg daily dose of rosuvastatin. Sequencing of SLCO1B1 coding regions revealed the patient was heterozygous for two SLCO1B1 deleterious variants, c.
View Article and Find Full Text PDFPublication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study.
Atherosclerosis
January 2025
Laboratoire de Biométrie et Biologie Evolutive UMR CNRS 5558, Université Lyon 1, Université de Lyon, Villeurbanne, France; Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.
Background And Aims: Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend dose adjustment for statin treatment according to known SLCO1B1 genotype to reduce SAMS. We hypothesized that the association between SLCO1B1 genotype and SAMS is misestimated because of publication bias.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!